Burning Rock Biotech (BNR) Current Leases (2021 - 2023)

Burning Rock Biotech has reported Current Leases over the past 3 years, most recently at $1.2 million for Q4 2023.

  • Quarterly results put Current Leases at $1.2 million for Q4 2023, down 77.1% from a year ago — trailing twelve months through Dec 2023 was $1.2 million (down 77.1% YoY), and the annual figure for FY2023 was $1.2 million, down 78.07%.
  • Current Leases for Q4 2023 was $1.2 million at Burning Rock Biotech, down from $5.2 million in the prior quarter.
  • Over the last five years, Current Leases for BNR hit a ceiling of $5.5 million in Q4 2021 and a floor of $1.2 million in Q4 2023.
  • Median Current Leases over the past 3 years was $5.2 million (2022), compared with a mean of $4.0 million.
  • Biggest five-year swings in Current Leases: fell 4.36% in 2022 and later tumbled 77.1% in 2023.
  • Burning Rock Biotech's Current Leases stood at $5.5 million in 2021, then fell by 4.36% to $5.2 million in 2022, then tumbled by 77.1% to $1.2 million in 2023.
  • The last three reported values for Current Leases were $1.2 million (Q4 2023), $5.2 million (Q4 2022), and $5.5 million (Q4 2021) per Business Quant data.